AAMU
ALNY icon

Amundi Asset Management US’s Alnylam Pharmaceuticals ALNY Stock Holding History

Amundi Asset Management US’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$30.5M Sell
216,007
-1,700
-0.8% -$256K 0.02% 558
2020
Q4 		$28.3M Sell
217,707
-32,294
-13% -$4.31M 0.02% 541
2020
Q3 		$36.4M Buy
250,001
+20,412
+9% +$2.9M 0.04% 401
2020
Q2 		$34M Buy
229,589
+53,155
+30% +$7.17M 0.04% 394
2020
Q1 		$19.2M Sell
176,434
-24,678
-12% -$2.85M 0.03% 415
2019
Q4 		$23.2M Buy
201,112
+22,721
+13% +$2.27M 0.03% 511
2019
Q3 		$14.3M Buy
178,391
+31,958
+22% +$2.53M 0.02% 612
2019
Q2 		$10.6M Sell
146,433
-3,226
-2% -$248K 0.01% 772
2019
Q1 		$14M Buy
149,659
+16,733
+13% +$1.4M 0.02% 635
2018
Q4 		$9.69K Buy
132,926
+4,697
+4% +$361K 0.01% 669
2018
Q3 		$11.2M Sell
128,229
-8,542
-6% -$859K 0.01% 709
2018
Q2 		$13.5M Buy
136,771
+33,869
+33% +$3.36M 0.02% 641
2018
Q1 		$12.3M Sell
102,902
-27,000
-21% -$3.48M 0.02% 628
2017
Q4 		$16.5M Buy
129,902
+34,330
+36% +$4.31M 0.03% 529
2017
Q3 		$11.2M Sell
95,572
-51,622
-35% -$4.41M 0.04% 290
2017
Q2 		$11.7M Buy
147,194
+59,938
+69% +$3.83M 0.04% 292
2017
Q1 		$4.47M Buy
+87,256
New +$4.03M 0.02% 424
2015
Q4 		– Sell
-632,698
Closed -$50.8M – 546
2015
Q3 		$50.8M Buy
632,698
+2,569
+0.4% +$285K 0.21% 124
2015
Q2 		$75.5M Buy
630,129
+145,305
+30% +$17.4M 0.28% 100
2015
Q1 		$50.6M Buy
484,824
+1,611
+0.3% +$163K 0.18% 144
2014
Q4 		$46.9M Buy
483,213
+158,926
+49% +$14.7M 0.17% 154
2014
Q3 		$25.3M Buy
+324,287
New +$20.9M 0.1% 215

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amundi Asset Management US's ALNY Position: Q1 2021 in Review

Amundi Asset Management US reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.78% in Q1 2021, selling an estimated $256K and leaving 216,007 shares worth $30.5M. The position accounts for 0.02% of the portfolio, ranked #558.

Amundi Asset Management US first reported a position in ALNY in Q3 2014 and has held it in 22 quarters since. The position peaked at $75.5M in Q2 2015. 391 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

  • Amundi Asset Management US held 216,007 shares of Alnylam Pharmaceuticals worth $30.5M as of Q1 2021.
  • Amundi Asset Management US sold 1,700 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $256K.
  • Alnylam Pharmaceuticals made up 0.02% of Amundi Asset Management US's portfolio in Q1 2021, its #558 holding.
  • Amundi Asset Management US first reported a position in Alnylam Pharmaceuticals in Q3 2014 and has held it in 22 quarters since.
  • Amundi Asset Management US's Alnylam Pharmaceuticals position peaked at $75.5M in Q2 2015.
  • 391 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.